Myasthenia Gravis - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Myasthenia Gravis - Pipeline Review, H1 2019’, provides an overview of the Myasthenia Gravis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myasthenia Gravis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myasthenia Gravis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Myasthenia Gravis

- The report reviews pipeline therapeutics for Myasthenia Gravis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Myasthenia Gravis therapeutics and enlists all their major and minor projects

- The report assesses Myasthenia Gravis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Myasthenia Gravis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Myasthenia Gravis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Myasthenia Gravis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Akari Therapeutics Plc

Alexion Pharmaceuticals Inc

Alpha Cancer Technologies Inc

Argenx SE

BioMarin Pharmaceutical Inc

Bristol-Myers Squibb Co

CuraVac Inc

Grifols SA

GT Biopharma Inc ...

Akari Therapeutics Plc

Alexion Pharmaceuticals Inc

Alpha Cancer Technologies Inc

Argenx SE

BioMarin Pharmaceutical Inc

Bristol-Myers Squibb Co

CuraVac Inc

Grifols SA

GT Biopharma Inc

HanAll Biopharma Co Ltd

Momenta Pharmaceuticals Inc

Neurotune AG

Novartis AG

Pfizer Inc

Protalex Inc

Ra Pharmaceuticals Inc

Toleranzia AB

Tolerion Inc

UCB SA

Table of Contents

Table of Contents

Table of Contents

Introduction

Myasthenia Gravis - Overview

Myasthenia Gravis - Therapeutics Development

Myasthenia Gravis - Therapeutics Assessment

Myasthenia Gravis - Companies ...

Table of Contents

Table of Contents

Introduction

Myasthenia Gravis - Overview

Myasthenia Gravis - Therapeutics Development

Myasthenia Gravis - Therapeutics Assessment

Myasthenia Gravis - Companies Involved in Therapeutics Development

Myasthenia Gravis - Drug Profiles

Myasthenia Gravis - Dormant Projects

Myasthenia Gravis - Discontinued Products

Myasthenia Gravis - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Myasthenia Gravis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products ...

List of Tables

Number of Products under Development for Myasthenia Gravis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Myasthenia Gravis - Pipeline by Akari Therapeutics Plc, H1 2019

Myasthenia Gravis - Pipeline by Alexion Pharmaceuticals Inc, H1 2019

Myasthenia Gravis - Pipeline by Alpha Cancer Technologies Inc, H1 2019

Myasthenia Gravis - Pipeline by Argenx SE, H1 2019

Myasthenia Gravis - Pipeline by BioMarin Pharmaceutical Inc, H1 2019

Myasthenia Gravis - Pipeline by Bristol-Myers Squibb Co, H1 2019

Myasthenia Gravis - Pipeline by CuraVac Inc, H1 2019

Myasthenia Gravis - Pipeline by Grifols SA, H1 2019

Myasthenia Gravis - Pipeline by GT Biopharma Inc, H1 2019

Myasthenia Gravis - Pipeline by HanAll Biopharma Co Ltd, H1 2019

Myasthenia Gravis - Pipeline by Momenta Pharmaceuticals Inc, H1 2019

Myasthenia Gravis - Pipeline by Neurotune AG, H1 2019

Myasthenia Gravis - Pipeline by Novartis AG, H1 2019

Myasthenia Gravis - Pipeline by Pfizer Inc, H1 2019

Myasthenia Gravis - Pipeline by Protalex Inc, H1 2019

Myasthenia Gravis - Pipeline by Ra Pharmaceuticals Inc, H1 2019

Myasthenia Gravis - Pipeline by Toleranzia AB, H1 2019

Myasthenia Gravis - Pipeline by Tolerion Inc, H1 2019

Myasthenia Gravis - Pipeline by UCB SA, H1 2019

Myasthenia Gravis - Dormant Projects, H1 2019

Myasthenia Gravis - Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Myasthenia Gravis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products ...

List of Figures

Number of Products under Development for Myasthenia Gravis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports